1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Esophageal Cancer - Pipeline Review, H2 2020, provides an overview of the Esophageal Cancer (Oncology) pipeline landscape.
Esophageal cancer is cancer that occurs in the esophagus. Symptoms include cough, difficulty swallowing, chest pain, pressure or burning and weight loss. Predisposing factors include age, smoking, obesity and bile reflux. Treatment includes chemotherapy, radiation therapy and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Esophageal Cancer - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Esophageal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Esophageal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Esophageal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 12, 77, 91, 7, 29, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 4 and 3 molecules, respectively.
Esophageal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Esophageal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Esophageal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Esophageal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Esophageal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Esophageal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Esophageal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Esophageal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionEsophageal Cancer - Overview
Esophageal Cancer - Therapeutics Development
Esophageal Cancer - Therapeutics Assessment
Esophageal Cancer - Companies Involved in Therapeutics Development
Esophageal Cancer - Drug Profiles
Esophageal Cancer - Dormant Projects
Esophageal Cancer - Discontinued Products
Esophageal Cancer - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Esophageal Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Esophageal Cancer - Pipeline by AbbVie Inc, H2 2020
- Esophageal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2020
- Esophageal Cancer - Pipeline by ADC Therapeutics SA, H2 2020
- Esophageal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2020
- Esophageal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2020
- Esophageal Cancer - Pipeline by Affimed GmbH, H2 2020
- Esophageal Cancer - Pipeline by AIMM Therapeutics BV, H2 2020
- Esophageal Cancer - Pipeline by Akeso Inc, H2 2020
- Esophageal Cancer - Pipeline by Alphamab Oncology, H2 2020
- Esophageal Cancer - Pipeline by Ambrx Inc, H2 2020
- Esophageal Cancer - Pipeline by amcure GmbH, H2 2020
- Esophageal Cancer - Dormant Projects, H2 2020
- Esophageal Cancer - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Esophageal Cancer, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Advanced Accelerator Applications SA
- Advenchen Laboratories LLC
- Affimed GmbH
- AIMM Therapeutics BV
- Akeso Inc
- Alphamab Oncology
- Ambrx Inc
- amcure GmbH
- AMI Onco Theranostics LLC
- Anhui Anke Biotechnology (Group) Co Ltd
- Anhui Kedgene Biotechnology Co Ltd
- Apexigen Inc
- Apollomics Inc
- Aprea Therapeutics Inc
- Arog Pharmaceuticals Inc
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Astellas Pharma Inc
- AstraZeneca Plc
- AVEO Pharmaceuticals Inc
- Bayer AG
- BeiGene Ltd
- Bicycle Therapeutics Plc
- BioMed Valley Discoveries Inc
- Biostage Inc
- BioStar Pharmaceuticals Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Cantargia AB
- Celldex Therapeutics Inc
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chi Cheung (Shanghai) Biomedical Co Ltd
- Chugai Pharmaceutical Co Ltd
- Coherent Biopharma
- Cotinga Pharmaceuticals Inc
- CStone Pharmaceuticals Co Ltd
- Curegenix Inc
- Cyclacel Pharmaceuticals Inc
- Cytlimic Inc
- CytomX Therapeutics Inc
- DAE HWA Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Delta-Fly Pharma Inc
- Dragonboat Biopharmaceutical (Shanghai)Co Ltd
- Dragonfly Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Genentech USA Inc
- Genmab AS
- GlaxoSmithKline Plc
- GLG Pharma SA
- GlycoNex Inc
- Glycotope GmbH
- Gossamer Bio Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou Anjie Biomedical Technology Co Ltd
- Guangzhou Saliai Stemcell Science and Technology Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- HEC Pharm Co Ltd
- Hualan Biological Engineering Inc
- Hutchison MediPharma Ltd
- Idera Pharmaceuticals Inc
- ImmuneSensor Therapeutics Inc
- Immunocore Ltd
- Immunomedics Inc
- ImmunoRestoration Inc
- Immvira Co Ltd
- Incyte Corp
- Innovent Biologics Inc
- Inovio Pharmaceuticals Inc
- Ipsen SA
- Jacobio Pharmaceuticals Co Ltd
- JenKem Technology Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Simcere Pharmaceutical Co Ltd
- Johnson & Johnson
- Kitov Pharma Ltd
- Kymab Ltd
- Leap Therapeutics Inc
- LEXEO Therapeutics LLC
- LIfT BioSciences Ltd
- Lycera Corp
- MaxiVAX SA
- Medical Guidance Systems LLC
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- Moderna Inc
- Modra Pharmaceuticals BV
- Molecular Templates Inc
- Myeloid Therapeutics Inc
- New B Innovation Ltd
- NGM Biopharmaceuticals Inc
- Novartis AG
- Novita Pharmaceuticals Inc
- OBI Pharma Inc
- Omeros Corp
- Omnitura Therapeutics Inc
- Oncolys BioPharma Inc
- Onconova Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- PDS Biotechnology Corp
- Peptron Inc
- Pfizer Inc
- Pieris Pharmaceuticals Inc
- Precigen Inc
- Puma Biotechnology Inc
- Quadriga BioSciences Inc
- Rafael Pharmaceuticals Inc
- Rakuten Medical Inc
- RAPT Therapeutics Inc
- RaQualia Pharma Inc
- Replimune Ltd
- Revolution Medicines Inc
- Rhizen Pharmaceuticals SA
- Scancell Holdings Plc
- Seattle Genetics Inc
- Seven and Eight Biopharmaceuticals Corp
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Keqi Pharmaceutical Technology Co Ltd
- Shanghai Miracogen Inc
- Shenyang Dongxing Pharmaceutical Co Ltd
- Shenzhen BinDeBio Ltd
- Shenzhen Hornetcorn Bio-technology Company Ltd
- Shenzhen NeoCura Biotechnology Corp
- Shionogi & Co Ltd
- Sino Biopharmaceutical Ltd
- Sinocelltech Ltd
- Smerud Medical Research International AS
- Soricimed Biopharma Inc
- Sorrento Therapeutics Inc
- Starpharma Holdings Ltd
- Steba Biotech SA
- Stemirna Therapeutics Inc
- Supratek Pharma Inc
- Sutro Biopharma Inc
- Suzhou Sinovent Pharmaceuticals Co Ltd
- Suzhou Stainwei Biotech Inc
- TAE Life Sciences LLC
- Taiho Oncology Inc
- Takara Bio Inc
- Telix Pharmaceuticals Ltd
- Tessa Therapeutics Ltd
- Themis Bioscience GmbH
- TOT Biopharm Co Ltd
- Transgene Biotek Ltd
- Transgene SA
- Turnstone Biologics Inc
- Tyg Oncology Ltd
- Viral Gene Inc
- VM Discovery Inc
- Xiangxue Life Sciences
- XuanZhu Pharma Co Ltd
- Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd
- Zymeworks Inc
